Breaking therapy resistance of follicular...Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy. more ➔
AML: Cellectis testing allogenic CAR-T cel... Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia. more ➔
Diabetes: J&J and Seventure Partners...European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, … more ➔
€66m Life Sciences Fund focused on Germa...Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch … more ➔
CHMP recommends several biologicsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting. more ➔
Roches lampalizumab halts geographic atr...A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trial, US and German researchers … more ➔
Epigenetic drugs set to boost immunoncolog... German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a … more ➔
AMD: Novartis challenges RegeneronFollowing shrinking sales for its wet AMD drug Lucentis, Novartis is back with convincing Phase III results of its anti-VEGF-A singe chain antibody fragment brolucizumab. In two pivotal studies the drug … more ➔
Evotec invests in Facio Therapies Evotec and co-investors support Dutch Facio Therapies BV with €4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy. more ➔
Delay in MAA for Asit Biotechs BTT009 Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs … more ➔
